skip to main content

Stage IIIA Adjuvant Melanoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardMelanoma & SkinStage IIIA Adjuvant MelanomaSCE Medical Oncology

A fit adult has completely resected stage IIIC cutaneous melanoma with no BRAF V600 mutation and no contraindication to immunotherapy. Which statement best reflects NICE TA766?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Offer adjuvant pembrolizumab after complete resection; eligibility does not depend on a BRAF V600 mutation

TA766 recommends pembrolizumab after complete resection of stage III melanoma. Unlike dabrafenib–trametinib, it is not conditional on a BRAF V600 mutation. Unresectable or measurable metastatic disease defines a different treatment setting; a clear postoperative scan does not remove the adjuvant rationale.

Reference: NICE TA766: adjuvant pembrolizumab after resection of stage III melanoma. https://www.nice.org.uk/guidance/ta766/